Summary
The renal handling and effects of an intravenous bolus of frusemide with and without plasma volume expansion with dextran or albumin, and with large variations in plasma albumin concentration, have been studied in five patients with the nephrotic syndrome.
Decreased renal sensitivity to frusemide was found in only one patient, who also had hypovolaemia and an activated renin-angiotensin-aldosterone system. Plasma volume expansion increased the diuresis but not the saluresis, and slightly increased renal sensitivity to frusemide.
An increase in albuminuria after albumin infusion did not reduce the sensitivity to frusemide. A decrease in plasma albumin concentration from 33 g·l−1 after albumin infusion to 23 g·l−1 after infusion of dextran caused a substantial increase in the renal clearance (from 84 to 123 ml·min−1), non-renal clearance (from 72 to 138 ml·min−1), and apparent volume of distribution (from 13 to 23 l) of frusemide, probably as a consequence of an increase in the unbound fraction. The rate of urinary excretion of frusemide was highest after albumin infusion, despite the fact that its renal clearance was lowest then.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brater DC (1985) Resistance to loop diuretics. Why it happens and what to do about it. Drugs 30: 427–443
Odlind B, Beermann B (1980) Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther 27: 784–790
Kaojarern S, Day B, Brater DC (1982) The time course of delivery of furosemide into urine: An independent determinant of overall response. Kidney Int 22: 69–74
Rane A, Villeneuve JP, Stone WJ, Nies AS, Wilkinson GR, Branch RA (1978) Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther 24: 199–207
Prandota J (1983) Pharmacokinetics of furosemide urinary elimination by nephrotic children. Pediatr Res 17: 141–147
Keller E, Hoppe-Seyler G, Schollmeyer P (1982) Disposition and diuretic effect of furosemide in the nephrotic syndrome. Clin Pharmacol Ther 32: 442–449
Smith DE, Hyneck ML, Berardi RR, Port FK (1985) Urinary protein binding, kinetics, and dynamics of furosemide in nephrotic patients. J Pharm Sci 74: 603–607
Green TP, Mirkin BL (1980) Resistance of proteinuric rats to furosemide: urinary drug protein binding as a determinant of drug effect. Life Sci 26: 623–630
Eder HA, Lauson HD, Chinard FP, Greif RI, Cotzias GC, van Slyke DD (1954) A study of the mechanisms of edema formation in patients with the nephrotic syndrome. J Clin Invest 33: 636–656
Dorhout Mees EJ (1984) Edema formation in the nephrotic syndrome. Contrib Nephrol 43: 64–75
Brown EA, Markandu ND, Sagnella GA, Jones BE, MacGregor GA (1985) Sodium retention in the nephrotic syndrome is due to an intrarenal defect: Evidence from steroid-induced remission. Nephron 39: 290–295
Koomans HA, Boer WH, Dorhout Mees EJ (1987) Renal function during recovery from minimal lesions nephrotic syndrome. Nephron 47: 173–178
Dorhout Mees EJ, Roos JC, Boer P, Yoe OH, Simatupang TA (1979) Observations on edema formation in nephrotic syndrome in adults with minimal lesions. Am J Med 67: 378–384
Geers AB, Koomans HA, Roos JC, Boer P, Dorhout Mees EJ (1984) Functional relationships in the nephrotic syndrome. Kidney Int 26: 324–330
Koomans HA, Geers AB, van der Meiracker AH, Roos JC, Boer P, Dorhout Mees EJ (1984) Effects of plasma volume expansion on renal salt handling in patients with the nephrotic syndrome. Am J Nephrol 4: 227–234
Brown EA, Markandu ND, Sagnella GA, Squires M, Jones BE, MacGregor GA (1982) Evidence that some mechanism other than the renin system causes sodium retention in nephrotic syndrome. Lancet 2: 1237–1240
Brown EA, Markandu ND, Sagnella GA, Jones BE, MacGregor GA (1984) Lack of effect of captopril on the sodium retention of the nephrotic syndrome. Nephron 37: 43–48
Chonko AM, Bay WH, Stein JH, Ferris TF (1977) The role of renin and aldosterone in the salt retention of edema. Am J Med 63: 881–889
Ichikawa HG, Rennke HG, Hoyer JR, Badr KF, Schor N, Troy JL, Lechene CP, Brenner BM (1983) Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest 71: 91–103
Hammarlund MM, Paalzow LK, Odlind B (1984) Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur J Clin Pharmacol 26: 197–207
McKenzie JK, Clements JA (1974) Simplified radioimmunoassay for serum aldosterone utilizing increased antibody specificity. J Clin Endocrinol Metab 38: 622–627
Führ J, Kaczmarczyk J, Krüttgen C-D (1955) Eine einfache colorimetrische Methode zur Inulinbestimmung für Nieren-Clearanceuntersuchungen bei Stoffwechselgesunden und Diabetikern. Klin Wochenschr 33: 729–730
Brun C (1951) A rapid method for the determination of paraaminohippuric acid in kidney function test. J Lab Clin Med 37: 955–958
Allgulander C, Beermann B, Sjögren A (1980) Frusemide pharmacokinetics in patients with liver disease. Clin Pharmacokinet 5: 570–575
Andreasen F, Jakobsen P (1974) Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure. Acta Pharmacol Toxicol 35: 49–57
Sjöström P, Odlind B, Beermann B, Hammarlund-Udenaes M (1987) Changes in furosemide pharmacokinetics induced by dehydration. In: Andreucci VE, Dal Canton A (eds) Diuretics: Basic pharmacological, and clinical aspects. Martinus Nijhoff, Boston, USA, pp 107–109
Bowman RH (1975) Renal secretion [35S]furosemide and its depression by albumin binding. Am J Physiol 229: 93–98
Hall S, Rowland M (1985) Influence of fraction unbound upon the renal clearance of furosemide in the isolated perfused rat kidney. J Pharmacol Exp Ther 232: 263–268
Green TP, Mirkin BL (1981) Furosemide disposition in normal and proteinuric rats: urinary drug-protein binding as a determinant of drug excretion. J Pharmacol Exp Ther 218: 122–127
Alván G, Beermann B, Hjelte L, Lind M, Lindholm A, Strandvik B (1988) Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis. Clin Pharmacol Ther 44: 436–441
Rowland M, Tozer T (1980) Clinical pharmacokinetics concepts and applications. Lea and Febiger, Philadelphia
Inoue M, Okajima K, Itoh K, Ando Y, Watanabe N, Yasaka T, Nagase S, Morino Y (1987) Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 32: 198–203
Danielsen H, Pedersen EB, Madsen M, Jensen T (1985) Abnormal renal sodium excretion in the nephrotic syndrome after furosemide: relation to glomerular filtration rate. Acta Med Scand 217: 513–518
Aurell M (1969) Renal response in man to plasma volume expansion and angiotensin. Scand J Clin Lab Invest 24 [Suppl 112]: 13–31
James J, Gordillo G, Metcoff J (1954) Effects of infusion of hyperoncotic dextran in children with the nephrotic syndrome. J Clin Invest 33: 1346–1357
Orloff J, Welt LG, Stowe L (1950) The effects of concentrated salt-poor albumin on the metabolism and excretion of water and electrolytes in nephrosis and toxemia of pregnancy. J Clin Invest 29: 770–780
Sjöström P, Beermann B, Odlind B (1988) Delayed tolerance to furosemide diuresis. Influence of ACE inhibition by lisinopril. Scand J Urol Nephrol 22: 317–325
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sjöström, P.A., Odlind, B.G., Beermann, B.A. et al. Pharmacokinetics and effects of frusemide in patients with the nephrotic syndrome. Eur J Clin Pharmacol 37, 173–180 (1989). https://doi.org/10.1007/BF00558227
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558227